Cladribine: all 91 studies that test it
Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- The HIt HArd and hiT Early in Multiple Sclerosis TrialRecruitingNCT07517185Phase 2
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingNCT07311746Phase 1/2
- A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)Not yet recruitingNCT07053020Phase 1/2
- Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingNCT06504459Phase 2
- Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).RecruitingNCT05961644Phase 2/3
- CAV Regimen for R/R Ph- B-ALLRecruitingNCT05657652Not applicable
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingNCT05466318Phase 3
- A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsRecruitingNCT05365035Phase 2
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingNCT05313958Phase 2/3
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingNCT04797767Phase 1/2
- A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine TabletsRecruitingNCT04550455Phase 4
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingNCT04375631Phase 1
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04047641Phase 1/2
- Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingNCT03586609Phase 2
- Therapy Optimisation for the Treatment of Hairy Cell LeukemiaRecruitingNCT02131753Phase 2/3
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingNCT01515527Phase 2
- Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaRecruitingNCT00412594Phase 2
- Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid LeukemiaCompletedNCT04848974Phase 1/2Results posted
- Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)CompletedNCT04783935Phase 4Results posted
- Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)CompletedNCT04776213Phase 4Results posted
- CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit PatientsCompletedNCT04195945Phase 2Results posted
- Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple SclerosisCompletedNCT03963375Phase 4Results posted
- Effects of Cladribine Tablets on the PK of Microgynon®CompletedNCT03745144Phase 1Results posted
- Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid NeoplasmCompletedNCT03531918Phase 1/2Results posted
- Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)CompletedNCT03369665Phase 4Results posted
- Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)CompletedNCT03364036Phase 4Results posted
- Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)TerminatedNCT03150004Phase 2Results posted
- Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid NeoplasmCompletedNCT03012672Phase 2Results posted
- Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSCompletedNCT02921061Phase 1/2Results posted
- Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
- Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
- Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT02096055Phase 2Results posted
- Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT02044796Phase 1/2Results posted
- Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaCompletedNCT00980395Phase 2Results posted
- Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis SubjectsCompletedNCT00938366Phase 1Results posted
- Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaActive, not recruitingNCT00923013Phase 2Results posted
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaCompletedNCT00764517Phase 2Results posted
- Oral Cladribine in Early Multiple Sclerosis (MS)CompletedNCT00725985Phase 3Results posted
- A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00718549Phase 3Results posted
- CLARITY Extension StudyCompletedNCT00641537Phase 3Results posted
- A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)CompletedNCT00436826Phase 2Results posted
- A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT00213135Phase 3Results posted
- Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or MyelodysplasiaCompletedNCT00136084Phase 3Results posted
- A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute LeukemiasWithdrawnNCT06474663Phase 1
- A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous CladribineTerminatedNCT06021600Phase 1
- Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid LeukemiaCompletedNCT05906914Phase 2
- Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis PatientsActive, not recruitingNCT05902429Phase 4
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnNCT05766514Phase 2
- Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALLStatus unknownNCT05578378Phase 2/3
- GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
- Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT05330364Phase 2
- Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AMLStatus unknownNCT05053425Not applicable
- Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic SyndromesActive, not recruitingNCT04861207Phase 2
- ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple SclerosisActive, not recruitingNCT04695080Phase 2/3
- Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AMLStatus unknownNCT04254640Phase 2
- Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid NeoplasmsTerminatedNCT04196010Phase 1
- Cladribine Tablets After Treatment With Natalizumab (CLADRINA)Active, not recruitingNCT04178005Phase 4
- Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)CompletedNCT04121403Phase 3
- Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin LymphomaStatus unknownNCT03602131Phase 2
- A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E MutationStatus unknownNCT03585686Phase 2
- Epacadostat, Cladribine and Cytarabine (ECC) in AMLWithdrawnNCT03491579Phase 1
- Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441048Phase 1
- CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AMLStatus unknownNCT03384225Phase 3
- CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AMLStatus unknownNCT03384212Phase 3
- Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic LeukemiaStatus unknownNCT03318419Phase 2
- Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT03181815Phase 2
- Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell LymphomaStatus unknownNCT03151876Phase 2
- Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT02250937Phase 2
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisActive, not recruitingNCT02205762Phase 2/3
- Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus RituximabCompletedNCT02157181Phase 2
- Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid LeukemiaStatus unknownNCT02072811Phase 3
- Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell HistiocytosisStatus unknownNCT01473797Phase 2
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)Status unknownNCT01439750Phase 1
- Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)Status unknownNCT01295593Phase 1/2
- Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AMLCompletedNCT01161550Phase 1
- Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00787969Phase 1
- Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and RituximabCompletedNCT00667329Phase 1
- Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT00656812Phase 2
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)CompletedNCT00483067Phase 2
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00258271Phase 1
- German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)CompletedNCT00198991Phase 4
- Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)Status unknownNCT00126321Phase 2
- Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and AdolescentsStatus unknownNCT00111345Phase 2/3
- Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLLCompletedNCT00072007Phase 2
- Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaCompletedNCT00053027Phase 2
- Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing CholangitisCompletedNCT00004762Phase 2
- Chemotherapy in Treating Children With Recurrent Acute Myeloid LeukemiaCompletedNCT00003178Phase 2
- Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00003174Phase 1
- Cladribine in Patients With Mantle Cell LymphomaCompletedNCT00002879Phase 2
- Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00002805Phase 2